BUDGET IMPACT OF SUBSTITUTING BIOSIMILAR TRASTUZUMAB (CT-P6) IN TREATING GASTRIC CANCER AND BREAST CANCER IN 28 EUROPEAN COUNTRIES
Author(s)
Suh D1, Lee S2, Suh D2
1Columbia University School of Public Health, New York, NY, USA, 2Chung-Ang University, Seoul, Korea, Republic of (South)
OBJECTIVES: The economic burden of cancer, in terms of number of patients and healthcare costs, has been rapidly increasing across Europe. This analysis was performed to estimate the budget impact of introducing biosimilar trastuzumab (CT-P6) and treatability of additional patients based on budget savings for 28 European countries from the payer perspective. METHODS: The budget impact model analyzed the financial impact of substituting originator trastuzumab with CT-P6 for the treatment of early breast cancer, metastatic breast cancer, and metastatic gastric cancer with a time horizon ranging from 1–3 years. Incidence rate in each year was estimated by annual change of the incidence rate which was calculated by fitting a regression line to the natural logarithm of the age-adjusted incidence rate for 2010-2015. Prevalence of study cancers in each year was projected using 1-5 year survival rates for new patients and 3-7 year survival rates for existing patients as well as market sales data, respectively. The base case analysis was performed under the assumption that the price of CT-P6 is 70% of the originator, the substitution rate of originator trastuzumab with CT-P6 in the first year is 20%, and growth in substitution rate each year is 5%. RESULTS: In analyses using the base case scenario over three years following CT-P6 introduction, total budget saving estimates ranged from €290 million to €562 million, depending on the scenario. The number of additional patients treated from savings ranged from 27,145–44,810. In the first year only, budget saving was estimated to be €53 million to €272 million and the number of additional patients treated from savings was 4,982–21,730 in different scenarios with a variety of substitution rates. CONCLUSIONS: Total possible savings from substitution to CT-P6 is substantial from both approaches to calculating budget impact based on epidemiological data and sales volume data.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PCN69
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Oncology